CRISPR Therapeutics AGOpportunity Rank #325(CRSP) Intrinsic Value & DCF Analysis (2026)
Current Price
$47.53
Last updated: Jul 24, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
No change vs previous
Trend Score
As of 2026-07-24
Still researching stocks one at a time?
Intrinziq helps you:
- Turn your stock-picking rules into repeatable strategies
- Find better setups across hundreds of stocks automatically
- Backtest your strategy before putting money to work
The intrinsic value of CRISPR Therapeutics AG (CRSP) is estimated at $17.00 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $47.53, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -60.50% long-term growth rate and a 10.00% discount rate (calculated: 9.95%), reflecting expected future free cash flow and cost of capital.
The intrinsic value of CRISPR Therapeutics AG (CRSP) is estimated at $17.00 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $47.53, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -60.50% long-term growth rate and a 10.00% discount rate (calculated: 9.95%), reflecting expected future free cash flow and cost of capital.Valuation Details
Capital Efficiency
The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.
Fundamental Details
Narrative Details
Trend Details
Investment Coach
- Price moves to at least a mid-teens discount to fair value
- Sustained improvement in ROIC versus WACC spread
- Meaningful shifts in narrative trend and fundamental score
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates CRISPR Therapeutics AG's intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
CRISPR Therapeutics AGHealthcare
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.